Kymera Therapeutics (NASDAQ:KYMR) Director Jeffrey Albers Sells 5,000 Shares of Stock

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Director Jeffrey Albers sold 5,000 shares of the firm’s stock in a transaction dated Monday, October 13th. The stock was sold at an average price of $59.19, for a total value of $295,950.00. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Kymera Therapeutics Trading Down 2.7%

Shares of NASDAQ KYMR opened at $58.26 on Wednesday. Kymera Therapeutics, Inc. has a one year low of $19.44 and a one year high of $60.00. The firm has a market capitalization of $4.17 billion, a PE ratio of -16.79 and a beta of 2.26. The business has a 50-day moving average price of $47.63 and a two-hundred day moving average price of $40.65.

Kymera Therapeutics (NASDAQ:KYMR) last announced its quarterly earnings data on Monday, August 11th. The company reported ($0.95) EPS for the quarter, missing analysts’ consensus estimates of ($0.83) by ($0.12). The business had revenue of $11.48 million for the quarter, compared to analyst estimates of $17.37 million. Kymera Therapeutics had a negative return on equity of 31.60% and a negative net margin of 616.03%.The company’s revenue was down 55.1% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.58) earnings per share. Research analysts anticipate that Kymera Therapeutics, Inc. will post -2.79 EPS for the current year.

Institutional Investors Weigh In On Kymera Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in KYMR. Farther Finance Advisors LLC lifted its holdings in Kymera Therapeutics by 642.9% in the 2nd quarter. Farther Finance Advisors LLC now owns 624 shares of the company’s stock worth $27,000 after purchasing an additional 540 shares during the last quarter. PNC Financial Services Group Inc. lifted its holdings in shares of Kymera Therapeutics by 506.6% during the second quarter. PNC Financial Services Group Inc. now owns 922 shares of the company’s stock worth $40,000 after buying an additional 770 shares during the last quarter. Osaic Holdings Inc. lifted its holdings in shares of Kymera Therapeutics by 18,050.0% during the second quarter. Osaic Holdings Inc. now owns 1,089 shares of the company’s stock worth $48,000 after buying an additional 1,083 shares during the last quarter. Caitong International Asset Management Co. Ltd acquired a new position in shares of Kymera Therapeutics during the first quarter worth approximately $68,000. Finally, KBC Group NV lifted its holdings in shares of Kymera Therapeutics by 15.2% during the first quarter. KBC Group NV now owns 2,479 shares of the company’s stock worth $68,000 after buying an additional 328 shares during the last quarter.

Analysts Set New Price Targets

Several equities research analysts recently commented on KYMR shares. Jefferies Financial Group set a $64.00 price target on Kymera Therapeutics and gave the company a “buy” rating in a research note on Wednesday, June 25th. Weiss Ratings reissued a “sell (d-)” rating on shares of Kymera Therapeutics in a research note on Wednesday, October 8th. Morgan Stanley started coverage on Kymera Therapeutics in a research note on Thursday, July 3rd. They issued an “overweight” rating and a $70.00 price target for the company. Oppenheimer boosted their price target on Kymera Therapeutics from $53.00 to $63.00 and gave the company an “outperform” rating in a research note on Wednesday, October 1st. Finally, Truist Financial boosted their price target on Kymera Therapeutics from $53.00 to $68.00 and gave the company a “buy” rating in a research note on Tuesday, September 30th. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $61.26.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.